A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

New England Journal of Medicine

Volumn 340, Issue 4, 1999, Pages 253-259

  Weinblatt, Michael E ^g   Kremer, Joel M ^a   Bankhurst, Arthur D ^b   Bulpitt, Ken J ^c   Fleischmann, Roy M ^h   Fox, Robert I ^d   Jackson, Christopher G ^e   Lange, Mary ^f   Burge, Daniel J ^f  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SCRIPPS CLINIC   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f AMGEN INC   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; FC RECEPTOR; HYBRID PROTEIN; METHOTREXATE; RECOMBINANT PROTEIN; STEROID; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INTRAARTICULAR DRUG ADMINISTRATION; MALE; MOUTH ULCER; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINITIS; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 0033611472     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901283400401     Document Type: Article

References (23)

1. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw Hill, 1994:1880-8.
2. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
3. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29: 822-31.
4. Thornton SC, Por SB, Penny R, Richter M, Shelley L, Breit SN. Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumor necrosis factor alpha. Clin Exp Immunol 1991;86:79-86.
5. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
6. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-8.
7. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.
8. von Asmuth EJU, van der Linden CJ, Leeuwenberg JFM, Buurman WA. Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-α-induced neutrophil toxicity. J Immunol 1991;147:3869-75.
9. Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61.
10. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
11. Saez-Llorens X, Jafari HS, Olsen KD, Nariuchi H, Hansen EJ, McCracken GH Jr. Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-α, and interleukin-1β. J Infect Dis 1991;163:1267-72.
12. Moreland LW, Blumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
13. Moreland LW, Schiff MH, Baumgartner SW, et al. Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc, ENBREL). J Investig Med 1998;46:228A. abstract.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
16. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
17. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, Disability and Pain Scale. J Rheumatol 1982;9:789-93.
18. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
19. Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA): draft guidance. Washington, D.C.: Food and Drug Administration, March 1998. (See http://www.fda.gov/cder/guidance/index.htm.) (Also available from NAPS [document no. 05498 for 52 pages], c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513.)
20. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
21. Alarcón GS. Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders. In: Koopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 13th ed. Vol. 1. Baltimore: Williams & Wilkins, 1997:679-98.
22. Weinblatt ME. Methotrexate. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:771-86.
23. Moreland LW, Baumgartner SW, Tindall EA, et al. Longterm treatment of DMARD failing rheumatoid arthritis patients with TNT receptor p75 Fc fusion protein (TNFR:Fc; ENBREL). J Investig Med 1998;46: 229A. abstract.